zinc sulfate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4275	7733-02-0

Description:

Molecule	Description
Synonyms: zinc sulfate heptahydrate zinc sulfate zincate sulfuric acid zinc salt	A compound given in the treatment of conditions associated with zinc deficiency such as acrodermatitis enteropathica. Externally, zinc sulfate is used as an astringent in lotions and eye drops. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995) Molecular weight: 161.44 Formula: O4SZn CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

zinc sulfate heptahydrate
zinc sulfate
zincate
sulfuric acid zinc salt

A compound given in the treatment of conditions associated with zinc deficiency such as acrodermatitis enteropathica. Externally, zinc sulfate is used as an astringent in lotions and eye drops. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)

Molecular weight: 161.44
Formula: O4SZn
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
0.60	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
May 5, 1987	FDA	ABRAXIS PHARM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Treatment failure	98.84	11.33	10	42941	199033	63247038
Drug intolerance	92.03	11.33	47	42904	308614	63137457
Systemic lupus erythematosus	90.66	11.33	16	42935	208902	63237169
Maternal exposure during pregnancy	88.92	11.33	20	42931	220042	63226029
Product use issue	87.20	11.33	21	42930	220499	63225572
Glossodynia	83.78	11.33	11	42940	178865	63267206
Product dose omission issue	82.23	11.33	345	42606	233968	63212103
Diarrhoea	79.72	11.33	785	42166	714581	62731490
Drug ineffective	78.48	11.33	403	42548	1044362	62401709
Product use in unapproved indication	70.89	11.33	17	42934	179063	63267008
Pericarditis	69.70	11.33	5	42946	131574	63314497
Infusion related reaction	69.34	11.33	40	42911	245481	63200590
Muscle spasms	65.29	11.33	243	42708	155907	63290164
Off label use	65.26	11.33	236	42715	674226	62771845
Wound	63.64	11.33	16	42935	163247	63282824
Toxicity to various agents	60.77	11.33	47	42904	247203	63198868
Arthropathy	57.24	11.33	45	42906	234747	63211324
Device expulsion	56.75	11.33	92	42859	34830	63411241
Unevaluable event	53.87	11.33	112	42839	51274	63394797
Therapeutic product effect decreased	52.39	11.33	33	42918	193154	63252917
Fall	51.81	11.33	447	42504	391887	63054184
Psoriasis	50.27	11.33	151	42800	86806	63359265
Drug hypersensitivity	50.25	11.33	83	42868	310604	63135467
Full blood count decreased	48.47	11.33	73	42878	25951	63420120
Intentional product use issue	47.08	11.33	14	42937	127878	63318193
Deep vein thrombosis	46.09	11.33	143	42808	83657	63362414
Helicobacter infection	45.16	11.33	5	42946	92780	63353291
Therapy cessation	45.15	11.33	77	42874	30380	63415691
Device dislocation	43.52	11.33	69	42882	25636	63420435
Hepatic enzyme increased	40.81	11.33	46	42905	202282	63243789
Fatigue	39.01	11.33	828	42123	887200	62558871
Therapeutic product effect incomplete	38.80	11.33	18	42933	125038	63321033
Drug abuse	37.70	11.33	3	42948	72515	63373556
Dizziness	36.24	11.33	447	42504	429478	63016593
Intentional overdose	36.07	11.33	4	42947	74148	63371923
Joint swelling	34.04	11.33	111	42840	327555	63118516
Folliculitis	33.69	11.33	4	42947	70313	63375758
Neuropathy peripheral	33.48	11.33	159	42792	113508	63332563
C-reactive protein increased	32.00	11.33	12	42939	94695	63351376
Asthenia	31.94	11.33	398	42553	383206	63062865
Pneumonia	31.49	11.33	458	42493	456309	62989762
Rheumatoid arthritis	31.48	11.33	79	42872	253740	63192331
General physical health deterioration	31.43	11.33	55	42896	201347	63244724
Plasma cell myeloma	30.55	11.33	72	42879	35833	63410238
Constipation	30.51	11.33	258	42693	224685	63221386
Nausea	30.14	11.33	773	42178	853698	62592373
Discomfort	28.65	11.33	43	42908	167331	63278740
Lower respiratory tract infection	27.87	11.33	29	42922	132278	63313793
Flatulence	27.82	11.33	68	42883	34634	63411437
Haemoglobin decreased	27.77	11.33	181	42770	145304	63300767
Exposure during pregnancy	27.57	11.33	39	42912	155508	63290563
Feeling abnormal	27.35	11.33	183	42768	148209	63297862
Laboratory test abnormal	26.28	11.33	57	42894	26855	63419216
Liver injury	25.44	11.33	5	42946	60515	63385556
Pulmonary embolism	24.65	11.33	149	42802	116535	63329536
Alopecia	23.56	11.33	133	42818	337403	63108668
Dehydration	22.01	11.33	196	42755	173158	63272913
Suicide attempt	21.82	11.33	7	42944	60911	63385160
Hypoxia	21.66	11.33	89	42862	59703	63386368
Blister	21.59	11.33	34	42917	129780	63316291
Injection site pain	21.51	11.33	156	42795	129644	63316427
Headache	21.13	11.33	569	42382	632672	62813399
Pelvic pain	21.13	11.33	35	42916	13484	63432587
Dyspnoea	20.88	11.33	590	42361	660723	62785348
Drug interaction	20.86	11.33	82	42869	229049	63217022
Dyspnoea exertional	20.47	11.33	88	42863	60214	63385857
Overdose	20.24	11.33	29	42922	115049	63331022
Dry skin	20.08	11.33	84	42867	56803	63389268
Irritable bowel syndrome	19.80	11.33	16	42935	82396	63363675
Hypoaesthesia	19.66	11.33	187	42764	168206	63277865
Respiratory symptom	19.54	11.33	17	42934	3330	63442741
Hypersensitivity	19.53	11.33	117	42834	292568	63153503
Ill-defined disorder	19.48	11.33	16	42935	81739	63364332
Memory impairment	19.46	11.33	129	42822	104129	63341942
Back pain	19.41	11.33	268	42683	263877	63182194
Hot flush	19.21	11.33	77	42874	51082	63394989
Injection site haemorrhage	18.81	11.33	47	42904	24267	63421804
Sinusitis fungal	18.80	11.33	13	42938	1818	63444253
Salpingo-oophorectomy unilateral	18.80	11.33	10	42941	871	63445200
Urinary tract infection	18.42	11.33	266	42685	264418	63181653
Vaginal haemorrhage	18.06	11.33	50	42901	27437	63418634
Fluid retention	17.93	11.33	84	42867	59602	63386469
Depression	17.67	11.33	207	42744	196285	63249786
Type 2 diabetes mellitus	17.17	11.33	11	42940	63857	63382214
Hip fracture	16.85	11.33	51	42900	29423	63416648
Condition aggravated	16.60	11.33	183	42768	402034	63044037
Embolism venous	16.39	11.33	15	42936	3139	63442932
Blood potassium decreased	16.38	11.33	64	42887	41962	63404109
Swelling	16.37	11.33	114	42837	275264	63170807
Eye swelling	16.21	11.33	44	42907	23874	63422197
Injection site erythema	16.18	11.33	104	42847	83070	63363001
Oedema peripheral	15.89	11.33	197	42754	189314	63256757
Influenza like illness	15.84	11.33	88	42863	66736	63379335
COVID-19	15.79	11.33	33	42918	113070	63333001
White blood cell count decreased	15.51	11.33	153	42798	138951	63307120
Sputum increased	15.39	11.33	13	42938	2446	63443625
Nasal congestion	14.60	11.33	85	42866	65575	63380496
Infection	14.55	11.33	93	42858	229080	63216991
Abdominal discomfort	14.45	11.33	143	42808	320742	63125329
Tricuspid valve incompetence	14.31	11.33	31	42920	14590	63431481
Balance disorder	14.29	11.33	102	42849	84320	63361751
Hypervolaemia	14.25	11.33	47	42904	28366	63417705
Skin discolouration	14.25	11.33	57	42894	37771	63408300
Impaired healing	14.24	11.33	30	42921	102512	63343559
Injection site reaction	13.83	11.33	77	42874	58447	63387624
Pulmonary arterial hypertension	13.79	11.33	40	42911	22537	63423534
Pleural effusion	13.74	11.33	109	42842	93101	63352970
Tremor	13.57	11.33	143	42808	132096	63313975
Product complaint	13.51	11.33	28	42923	12781	63433290
Pulmonary hypertension	13.24	11.33	55	42896	37068	63409003
Adverse event	12.92	11.33	16	42935	67543	63378528
Atrial fibrillation	12.86	11.33	128	42823	116508	63329563
Administration site swelling	12.77	11.33	9	42942	1298	63444773
Foetal exposure during pregnancy	12.70	11.33	3	42948	31959	63414112
Intestinal dilatation	12.67	11.33	10	42941	1712	63444359
Red blood cell sedimentation rate increased	12.63	11.33	7	42944	43975	63402096
Coma	12.57	11.33	15	42936	64349	63381722
Fibromyalgia	12.50	11.33	22	42929	80398	63365673
Plasma cell myeloma recurrent	12.43	11.33	13	42938	3200	63442871
International normalised ratio increased	12.27	11.33	63	42888	46362	63399709
Prescribed overdose	12.09	11.33	4	42947	34149	63411922
Abdominal distension	12.07	11.33	100	42851	86515	63359556
Cardiac failure congestive	11.97	11.33	105	42846	92328	63353743
Body height decreased	11.79	11.33	23	42928	10055	63436016
Premature delivery	11.73	11.33	3	42948	30278	63415793
Hospice care	11.68	11.33	20	42931	7912	63438159
Platelet count decreased	11.64	11.33	125	42826	115997	63330074
Chest pain	11.62	11.33	208	42743	215751	63230320
Thrombosis	11.40	11.33	79	42872	64676	63381395
Injection site mass	11.34	11.33	33	42918	18623	63427448

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Off label use	57.63	11.96	139	25322	419385	34512085
Product use in unapproved indication	56.43	11.96	9	25452	117490	34813980
Completed suicide	53.29	11.96	5	25456	98163	34833307
Fatigue	49.51	11.96	448	25013	370205	34561265
Plasma cell myeloma	47.89	11.96	99	25362	41938	34889532
Drug interaction	46.31	11.96	58	25403	225888	34705582
Diarrhoea	44.52	11.96	456	25005	389456	34542014
Product dose omission issue	42.31	11.96	186	25275	119525	34811945
Respiratory tract infection bacterial	41.57	11.96	22	25439	1760	34929710
Toxicity to various agents	40.45	11.96	52	25409	200310	34731160
Anal inflammation	38.94	11.96	19	25442	1281	34930189
Respiratory tract infection viral	37.02	11.96	23	25438	2494	34928976
Full blood count decreased	36.81	11.96	55	25406	18033	34913437
SARS-CoV-2 test negative	33.86	11.96	16	25445	1004	34930466
Laboratory test abnormal	33.21	11.96	56	25405	20335	34911135
White blood cell count decreased	31.97	11.96	146	25315	95299	34836171
Asthenia	30.39	11.96	292	25169	244959	34686511
Adverse drug reaction	29.83	11.96	66	25395	29276	34902194
Fall	27.86	11.96	247	25214	202638	34728832
General physical health deterioration	25.13	11.96	34	25427	128235	34803235
Viral infection	23.06	11.96	44	25417	17579	34913891
Therapy cessation	21.75	11.96	42	25419	16931	34914539
Overdose	21.21	11.96	21	25440	91038	34840432
Accident	21.05	11.96	22	25439	5025	34926445
Intentional product misuse	20.77	11.96	4	25457	45607	34885863
Psoriasis	19.99	11.96	68	25393	38744	34892726
Platelet count decreased	19.19	11.96	151	25310	119566	34811904
Pneumonia	19.07	11.96	370	25091	362257	34569213
Interstitial lung disease	19.05	11.96	12	25449	65270	34866200
Influenza	18.92	11.96	79	25382	49587	34881883
Proctalgia	18.77	11.96	22	25439	5701	34925769
Body temperature increased	18.71	11.96	40	25421	17328	34914142
Drug ineffective	17.62	11.96	231	25230	456520	34474950
Treatment failure	17.62	11.96	6	25455	46691	34884779
Back pain	17.58	11.96	150	25311	121639	34809831
Dizziness	17.05	11.96	238	25223	218283	34713187
Neuropathy peripheral	16.79	11.96	111	25350	83152	34848318
Muscle spasms	16.36	11.96	102	25359	74899	34856571
Foetal exposure during pregnancy	16.01	11.96	4	25457	38097	34893373
Rash	15.94	11.96	239	25222	222513	34708957
Peripheral swelling	15.41	11.96	102	25359	76439	34855031
Sinusitis	15.10	11.96	65	25396	41337	34890133
Hepatic function abnormal	14.62	11.96	7	25454	44356	34887114
Thrombosis	14.57	11.96	74	25387	50384	34881086
Multiple organ dysfunction syndrome	14.28	11.96	21	25440	76545	34854925
Regurgitation	14.27	11.96	11	25450	1688	34929782
Coma	13.88	11.96	8	25453	45670	34885800
Eructation	13.58	11.96	17	25444	4714	34926756
Suicide attempt	13.15	11.96	6	25455	39110	34892360
Influenza like illness	13.00	11.96	47	25414	27587	34903883
Flatulence	12.59	11.96	39	25422	21159	34910311
Small intestinal obstruction	12.44	11.96	31	25430	14835	34916635
Cardiac disorder	12.28	11.96	63	25398	43063	34888407
Constipation	12.24	11.96	153	25308	136829	34794641

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	141.41	10.58	6	54224	245761	79444397
Product use in unapproved indication	107.63	10.58	20	54210	250339	79439819
Toxicity to various agents	99.94	10.58	84	54146	421456	79268702
Off label use	96.58	10.58	307	53923	906908	78783250
Drug abuse	93.46	10.58	4	54226	162687	79527471
Product dose omission issue	89.31	10.58	369	53861	247168	79442990
Treatment failure	86.66	10.58	8	54222	170478	79519680
Drug intolerance	75.31	10.58	43	54187	264076	79426082
Drug ineffective	73.77	10.58	433	53797	1080480	78609678
Device expulsion	68.13	10.58	86	54144	25775	79664383
Drug interaction	65.22	10.58	114	54116	415069	79275089
Diarrhoea	65.15	10.58	897	53333	879592	78810566
Product use issue	64.48	10.58	31	54199	209791	79480367
Therapy cessation	62.07	10.58	100	54130	37462	79652696
Fall	60.84	10.58	551	53679	487078	79203080
Plasma cell myeloma	56.47	10.58	117	54113	53142	79637016
Asthenia	51.53	10.58	553	53677	511136	79179022
Systemic lupus erythematosus	51.35	10.58	10	54220	121139	79569019
Intentional overdose	51.18	10.58	6	54224	105954	79584204
Dizziness	50.28	10.58	563	53667	525878	79164280
Deep vein thrombosis	49.79	10.58	188	54042	120731	79569427
Muscle spasms	49.10	10.58	242	53988	174488	79515670
Infusion related reaction	48.47	10.58	51	54179	230186	79459972
Fatigue	47.89	10.58	892	53338	928835	78761323
General physical health deterioration	46.51	10.58	72	54158	275166	79414992
Drug hypersensitivity	46.07	10.58	83	54147	298833	79391325
Full blood count decreased	41.07	10.58	69	54161	26750	79663408
Maternal exposure during pregnancy	40.68	10.58	21	54209	136517	79553641
Therapeutic product effect incomplete	40.43	10.58	23	54207	141622	79548536
Respiratory tract infection bacterial	39.82	10.58	22	54208	2055	79688103
Device dislocation	38.69	10.58	66	54164	25904	79664254
Intentional product misuse	37.99	10.58	9	54221	95156	79595002
Overdose	37.44	10.58	42	54188	184164	79505994
Glossodynia	37.10	10.58	12	54218	103325	79586833
Anal inflammation	35.50	10.58	18	54212	1412	79688746
Pulmonary embolism	33.75	10.58	216	54014	171438	79518720
Dehydration	32.69	10.58	284	53946	247903	79442255
C-reactive protein increased	32.67	10.58	24	54206	129003	79561155
Joint swelling	31.72	10.58	96	54134	288550	79401608
Duodenal ulcer perforation	31.36	10.58	4	54226	66207	79623951
Arthropathy	31.19	10.58	45	54185	177066	79513092
Helicobacter infection	31.17	10.58	5	54225	69699	79620459
Pericarditis	31.10	10.58	16	54214	104220	79585938
Pneumonia	30.33	10.58	623	53607	659623	79030535
Haemoglobin decreased	30.21	10.58	256	53974	221863	79468295
Respiratory tract infection viral	29.65	10.58	24	54206	4235	79685923
Intentional product use issue	29.49	10.58	36	54194	152076	79538082
Unevaluable event	28.55	10.58	93	54137	55492	79634666
Rheumatoid arthritis	27.73	10.58	63	54167	208407	79481751
SARS-CoV-2 test negative	27.61	10.58	15	54215	1356	79688802
Fluid retention	27.46	10.58	107	54123	69702	79620456
Dyspnoea exertional	26.90	10.58	124	54106	86949	79603209
Hypoxia	26.88	10.58	140	54090	103103	79587055
Therapeutic product effect decreased	26.59	10.58	44	54186	163819	79526339
Coma	26.43	10.58	18	54212	100631	79589527
Hypervolaemia	26.19	10.58	76	54154	42614	79647544
Dyspnoea	25.93	10.58	764	53466	856261	78833897
Suicide attempt	25.85	10.58	12	54218	82920	79607238
Lower respiratory tract infection	24.61	10.58	31	54199	129189	79560969
Mental status changes	24.23	10.58	100	54130	66859	79623299
Nausea	24.18	10.58	835	53395	956361	78733797
Hospice care	23.57	10.58	32	54198	10292	79679866
Feeling abnormal	22.98	10.58	186	54044	159013	79531145
Flatulence	22.41	10.58	72	54158	42652	79647506
Hip fracture	22.08	10.58	58	54172	30703	79659455
Therapeutic response decreased	21.90	10.58	9	54221	66844	79623314
Pelvic pain	21.26	10.58	35	54195	13346	79676812
Wound	20.97	10.58	29	54201	116150	79574008
Eosinophilia	20.85	10.58	3	54227	45342	79644816
Hepatic function abnormal	20.67	10.58	12	54218	73095	79617063
Folliculitis	20.65	10.58	6	54224	55374	79634784
Hepatic enzyme increased	20.58	10.58	60	54170	182550	79507608
Aspartate aminotransferase increased	20.56	10.58	163	54067	138478	79551680
Injection site pain	20.56	10.58	155	54075	129683	79560475
Blood potassium decreased	20.54	10.58	74	54156	46438	79643720
White blood cell count decreased	20.05	10.58	206	54024	188082	79502076
Haematocrit decreased	19.45	10.58	88	54142	61224	79628934
Back pain	19.22	10.58	302	53928	303878	79386280
Influenza like illness	19.19	10.58	98	54132	71609	79618549
Headache	18.97	10.58	580	53650	653192	79036966
Cholestasis	18.79	10.58	6	54224	52103	79638055
Interstitial lung disease	18.48	10.58	30	54200	112570	79577588
Platelet count decreased	18.42	10.58	208	54022	194456	79495702
Small intestinal obstruction	18.14	10.58	50	54180	27222	79662936
Depression	18.03	10.58	226	54004	216564	79473594
Irritable bowel syndrome	17.91	10.58	10	54220	62231	79627927
Viral infection	17.79	10.58	67	54163	42949	79647209
Myelosuppression	17.77	10.58	3	54227	40293	79649865
Psoriasis	17.76	10.58	113	54117	89474	79600684
International normalised ratio increased	17.50	10.58	108	54122	84613	79605545
Constipation	17.12	10.58	279	53951	282771	79407387
Hospitalisation	16.94	10.58	116	54114	94120	79596038
Chills	16.91	10.58	175	54055	160059	79530099
Oedema peripheral	16.90	10.58	253	53977	252035	79438123
Vaginal haemorrhage	16.55	10.58	42	54188	21775	79668383
Salpingo-oophorectomy unilateral	16.45	10.58	9	54221	825	79689333
Rhabdomyolysis	16.44	10.58	28	54202	103103	79587055
Pulmonary arterial hypertension	15.98	10.58	49	54181	28317	79661841
Complication associated with device	15.76	10.58	36	54194	17460	79672698
Exposure during pregnancy	15.63	10.58	28	54202	101104	79589054
Injection site haemorrhage	15.56	10.58	48	54182	27822	79662336
Pleural effusion	15.50	10.58	159	54071	145103	79545055
Eructation	15.30	10.58	27	54203	10882	79679276
Pulmonary hypertension	15.24	10.58	69	54161	48011	79642147
Cytomegalovirus infection	15.22	10.58	5	54225	42639	79647519
Eye swelling	15.17	10.58	46	54184	26422	79663736
Injection site erythema	15.11	10.58	98	54132	78099	79612059
Liver injury	15.03	10.58	10	54220	56604	79633554
Acute respiratory failure	14.98	10.58	80	54150	59461	79630697
Product complaint	14.94	10.58	30	54200	13319	79676839
Multiple sclerosis relapse	14.91	10.58	67	54163	46466	79643692
Agranulocytosis	14.85	10.58	6	54224	45024	79645134
Depressed level of consciousness	14.72	10.58	27	54203	96625	79593533
Abdominal pain	14.49	10.58	357	53873	389212	79300946
Tremor	14.43	10.58	178	54052	169905	79520253
Cardiac failure congestive	14.31	10.58	154	54076	142248	79547910
Nasal congestion	14.22	10.58	95	54135	76457	79613701
Accident	13.89	10.58	23	54207	8808	79681350
Fibromyalgia	13.81	10.58	14	54216	64326	79625832
Abdominal distension	13.75	10.58	133	54097	119517	79570641
Sinusitis fungal	13.69	10.58	12	54218	2362	79687796
Urinary tract infection	13.54	10.58	262	53968	274250	79415908
Condition aggravated	13.42	10.58	250	53980	500874	79189284
Ill-defined disorder	13.40	10.58	15	54215	65860	79624298
Drug resistance	13.32	10.58	6	54224	42207	79647951
Hypoaesthesia	13.25	10.58	183	54047	179169	79510989
Cytokine release syndrome	13.24	10.58	4	54226	35994	79654164
Multiple organ dysfunction syndrome	13.19	10.58	40	54190	120206	79569952
Dysgeusia	13.17	10.58	75	54155	57102	79633056
Transfusion	13.11	10.58	38	54192	21292	79668866
Proctalgia	13.07	10.58	24	54206	9977	79680181
Tricuspid valve incompetence	12.97	10.58	36	54194	19676	79670482
Blister	12.92	10.58	40	54190	119436	79570722
Gamma-glutamyltransferase increased	12.79	10.58	11	54219	54669	79635489
Memory impairment	12.74	10.58	124	54106	111610	79578548
Altered state of consciousness	12.67	10.58	7	54223	43815	79646343
Drug reaction with eosinophilia and systemic symptoms	12.66	10.58	15	54215	64229	79625929
Flushing	12.66	10.58	103	54127	88165	79601993
Illness	12.64	10.58	8	54222	46503	79643655
Prescribed overdose	12.57	10.58	5	54225	37878	79652280
Neuropathy peripheral	12.47	10.58	149	54081	141156	79549002
Infection	12.35	10.58	105	54125	241607	79448551
Discomfort	12.25	10.58	44	54186	125573	79564585
Cellulitis	11.93	10.58	120	54110	108940	79581218
Laboratory test abnormal	11.86	10.58	44	54186	28004	79662154
Diabetes mellitus	11.85	10.58	22	54208	78368	79611790
COVID-19	11.84	10.58	61	54169	157613	79532545
Anaphylactic shock	11.54	10.58	5	54225	35991	79654167
Neoplasm progression	11.37	10.58	11	54219	51671	79638487
Renal impairment	11.31	10.58	62	54168	157721	79532437
Pneumocystis jirovecii pneumonia	11.27	10.58	4	54226	32504	79657654
Cardiac disorder	11.26	10.58	80	54150	65677	79624481
Disease progression	11.24	10.58	182	54048	184180	79505978
Chest pain	11.19	10.58	261	53969	282043	79408115
Respiratory symptom	11.16	10.58	15	54215	4776	79685382
Laryngeal pain	11.10	10.58	17	54213	6097	79684061
Red blood cell count decreased	11.06	10.58	72	54158	57441	79632717
Cardiac failure	11.02	10.58	61	54169	154781	79535377
Osteonecrosis of jaw	10.99	10.58	8	54222	43218	79646940
Application site discolouration	10.93	10.58	7	54223	857	79689301
Thrombosis	10.93	10.58	96	54134	84004	79606154
Blood pressure fluctuation	10.91	10.58	18	54212	67127	79623031
Heavy menstrual bleeding	10.65	10.58	27	54203	13984	79676174
Injection site nodule	10.64	10.58	13	54217	3767	79686391

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A12CB01	ALIMENTARY TRACT AND METABOLISM MINERAL SUPPLEMENTS OTHER MINERAL SUPPLEMENTS Zinc
ATC	B05XA18	BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS I.V. SOLUTION ADDITIVES Electrolyte solutions
CHEBI has role	CHEBI:33287	fertilizers
MeSH PA	D001252	Astringents
MeSH PA	D003879	Dermatologic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Red eye	indication	75705005
Zinc deficiency	indication	238124008
Hereditary acrodermatitis enteropathica	off-label use	37702000
Viral gastroenteritis	off-label use	111843007
Impotence	off-label use	397803000
Attention deficit hyperactivity disorder	off-label use	406506008
Hypocupremia	contraindication	19577007
Sarcoidosis	contraindication	31541009	DOID:11335
Dehydration	contraindication	34095006
Hyperthyroidism	contraindication	34486009	DOID:7998
Depressive disorder	contraindication	35489007
Hypertensive disorder	contraindication	38341003	DOID:10763
Low blood pressure	contraindication	45007003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Heart disease	contraindication	56265001	DOID:114
Diarrhea	contraindication	62315008
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Hypercalciuria	contraindication	71938000
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007
Eye infection	contraindication	128351009
Angina pectoris	contraindication	194828000
Disease of liver	contraindication	235856003	DOID:409
Injury of eye region	contraindication	282752000
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Psychiatric Disturbance	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	ZINC SULFATE	FRESENIUS KABI USA	A216145	Dec. 27, 2022	RX	SOLUTION	INTRAVENOUS	Aug. 14, 2023	COMPETITIVE GENERIC THERAPY
EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (1ML)	TRALEMENT	AM REGENT	N209376	July 2, 2020	RX	SOLUTION	INTRAVENOUS	April 30, 2024	NEW CHEMICAL ENTITY
EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (5ML)	TRALEMENT	AM REGENT	N209376	Dec. 2, 2020	RX	SOLUTION	INTRAVENOUS	April 30, 2024	NEW CHEMICAL ENTITY
EQ 60MCG COPPER/ML;EQ 3MCG BASE/ML;EQ 6MCG SELENIUM/ML;EQ 1000MCG BASE/ML (1ML)	MULTRYS	AM REGENT	N209376	June 30, 2021	RX	SOLUTION	INTRAVENOUS	April 30, 2024	NEW CHEMICAL ENTITY

Bioactivity Summary:

None

External reference:

ID	Source
4017710	VUID
N0000146080	NUI
D06371	KEGG_DRUG
7446-20-0	SECONDARY_CAS_RN
4017651	VANDF
4017710	VANDF
C0078794	UMLSCUI
CHEBI:35176	CHEBI
CHEMBL1200929	ChEMBL_ID
D019287	MESH_DESCRIPTOR_UI
DB09322	DRUGBANK_ID
24424	PUBCHEM_CID
1311282	RXNORM
1512	MMSL
21079	MMSL
5710	MMSL
72010	MMSL
7398	MMSL
d04057	MMSL
000844	NDDF
001944	NDDF
007499	NDDF
387367007	SNOMEDCT_US
6625006	SNOMEDCT_US
N57JI2K7WP	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Multitrace-4 Neonatal	HUMAN PRESCRIPTION DRUG LABEL	4	0517-6202	INJECTION, SOLUTION	6.60 mg	INTRAVENOUS	UNAPPROVED DRUG OTHER	14 sections
Multitrace-5	HUMAN PRESCRIPTION DRUG LABEL	5	0517-8201	INJECTION, SOLUTION, CONCENTRATE	22 mg	INTRAVENOUS	UNAPPROVED DRUG OTHER	14 sections
Multitrace-5	HUMAN PRESCRIPTION DRUG LABEL	5	0517-8210	INJECTION, SOLUTION, CONCENTRATE	22 mg	INTRAVENOUS	UNAPPROVED DRUG OTHER	14 sections
Multitrace-5	HUMAN PRESCRIPTION DRUG LABEL	5	0517-8510	INJECTION, SOLUTION	4.39 mg	INTRAVENOUS	UNAPPROVED DRUG OTHER	14 sections
Multitrace -4 Pediatric	HUMAN PRESCRIPTION DRUG LABEL	4	0517-9203	INJECTION, SOLUTION, CONCENTRATE	4.39 mg	INTRAVENOUS	UNAPPROVED DRUG OTHER	14 sections
Trace Elements 4	HUMAN PRESCRIPTION DRUG LABEL	4	0517-9310	INJECTION, SOLUTION	2.20 mg	INTRAVENOUS	UNAPPROVED DRUG OTHER	14 sections